110 related articles for article (PubMed ID: 15535272)
1. [Postoperative hormone (endocrine) therapy in endometrial carcinoma].
Hiura M; Oshita T; Nogawa T; Yokoyama T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():381-5. PubMed ID: 15535272
[No Abstract] [Full Text] [Related]
2. [Hormone therapy for uterine corpus cancer--introduction].
Sugiyama T; Izutsu T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():370-4. PubMed ID: 15535270
[No Abstract] [Full Text] [Related]
3. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
4. [Hormone therapy for breast cancer].
Saito Y; Suzuki Y; Tokuda Y
Nihon Rinsho; 2007 Jun; 65 Suppl 6():543-8. PubMed ID: 17682208
[No Abstract] [Full Text] [Related]
5. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
6. Hormonal therapy of endometrial stromal sarcoma.
Reich O; Regauer S
Curr Opin Oncol; 2007 Jul; 19(4):347-52. PubMed ID: 17545798
[TBL] [Abstract][Full Text] [Related]
7. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
8. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
9. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Forbes JF
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
Baum M
Eur J Cancer; 2005 Aug; 41(12):1667-77. PubMed ID: 16046117
[TBL] [Abstract][Full Text] [Related]
11. [Conservative hormonal therapy for endometrial cancer].
Susumu N; Aoki D; Tamada Y; Banno K; Suzuki A; Suzuki N; Nozawa S
Nihon Rinsho; 2004 Oct; 62 Suppl 10():375-80. PubMed ID: 15535271
[No Abstract] [Full Text] [Related]
12. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma.
Giannopoulos T; Butler-Manuel S; Tailor A
Gynecol Oncol; 2004 Dec; 95(3):762-4. PubMed ID: 15582001
[TBL] [Abstract][Full Text] [Related]
13. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
14. [Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer].
Mitsuyama S; Kuroda Y; Ohsato K; Nakamura Y; Murakami F; Nishikata F; Ikeda S; Egami T; Mori A; Ohe H
Gan To Kagaku Ryoho; 1996 Aug; 23(9):1153-60. PubMed ID: 8751803
[TBL] [Abstract][Full Text] [Related]
15. [Endometrial stromal sarcoma: complete response to therapy with aromatase-inhibitor, anastrozole].
Lisianskaia AS; Manikhas GM; Fadeeva EP; Fedosenko KV; Tapil'skaia NI
Vopr Onkol; 2010; 56(1):91-3. PubMed ID: 20361625
[No Abstract] [Full Text] [Related]
16. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Singh Ranger G
J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
[TBL] [Abstract][Full Text] [Related]
17. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Buzdar AU; Cuzick J
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
[TBL] [Abstract][Full Text] [Related]
18. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
19. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
[TBL] [Abstract][Full Text] [Related]
20. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Bruntsch U
MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697
[No Abstract] [Full Text] [Related]
[Next] [New Search]
